Want to see LONA full AI Analyst Report?
LONA Stock Chart & Stats
$8.86
-$0.02(-3.33%)
At close: 4:00 PM EST
$8.86
-$0.02(-3.33%)
Day’s Range― - ―
52-Week Range$2.85 - $14.21
Previous CloseN/A
VolumeN/A
Average Volume (3M)41.47K
Market Cap
$88.30M
Enterprise Value$317.34K
Total Cash (Recent Filing)$67.68M
Total Debt (Recent Filing)$691.00K
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Aug 17, 2026EPS Estimate
-1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-30.13
Shares Outstanding9,393,514
10 Day Avg. Volume36,543
30 Day Avg. Volume41,474
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-0.71
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$18.00Price Target Upside103.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.57
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentATH-1105 has demonstrated a favorable safety profile and was well-tolerated in a Phase 1 study, supporting continued clinical development.
Financial StabilityThere is now sufficient cash runway to support operations through the data readout following the company's restructuring and downsizing.
Regulatory EnvironmentThe development pathway for ALS is attractive due to the FDA's flexibility and recent accelerated approval of Tofersen using Nf-L as a surrogate biomarker.
Bears Say
Financial ChallengesGiven the discontinuation of fosgonimeton, ATHA has significantly restructured and reduced future operating expenses, indicating financial challenges.
Partnership ChallengesThe company is unlikely to advance the program without a partner, and a partnership is unlikely to materialize due to the challenging ALS space and negative data for prior lead asset.
Strategic UncertaintyA strategic transaction for ATHA could ultimately result, but visibility on when and with whom is low, leading analysts to recommend looking elsewhere for growth opportunities.
LeonaBio News
LONA FAQ
What was LeonaBio’s price range in the past 12 months?
LeonaBio lowest stock price was $2.85 and its highest was $14.21 in the past 12 months.
What is LeonaBio’s market cap?
LeonaBio’s market cap is $88.30M.
When is LeonaBio’s upcoming earnings report date?
LeonaBio’s upcoming earnings report date is Aug 17, 2026 which is in 48 days.
How were LeonaBio’s earnings last quarter?
LeonaBio released its earnings results on May 07, 2026. The company reported -$1.73 earnings per share for the quarter, beating the consensus estimate of -$2.277 by $0.547.
Is LeonaBio overvalued?
According to Wall Street analysts LeonaBio’s price is currently Undervalued.
Does LeonaBio pay dividends?
LeonaBio does not currently pay dividends.
What is LeonaBio’s EPS estimate?
LeonaBio’s EPS estimate is -1.12.
How many shares outstanding does LeonaBio have?
LeonaBio has 9,393,514 shares outstanding.
What happened to LeonaBio’s price movement after its last earnings report?
LeonaBio reported an EPS of -$1.73 in its last earnings report, beating expectations of -$2.277. Following the earnings report the stock price went up 1.826%.
Which hedge fund is a major shareholder of LeonaBio?
Currently, no hedge funds are holding shares in LONA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LeonaBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.12%
12-Months-Change
Fundamentals
Return on Equity
-381.01%
Trailing 12-Months
Asset Growth
64.53%
Trailing 12-Months
Company Description
LeonaBio
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
LONA Stock 12 Month Forecast
Average Price Target
$18.00
▲(103.16% Upside)
Technical Analysis
Ownership Overview
40.88% Insiders
1.73% Mutual Funds
7.38% Other Institutional Investors
46.35% Public Companies and
Individual Investors